dalteparin and Phlegmasia Alba Dolens studies

Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)

Phlegmasia Alba Dolens: Inflammation that is characterized by swollen, pale, and painful limb. It is usually caused by DEEP VEIN THROMBOSIS in a FEMORAL VEIN, following PARTURITION or an illness. This condition is also called milk leg or white leg.

Research Excerpts

Excerpt	Relevance	Reference
"Dalteparin is superior to the NSAID ibuprofen in preventing extension of superficial thrombophlebitis during the 14-day treatment period with similar relief of pain and no increase in bleeding."	9.16	A randomized trial of dalteparin compared with ibuprofen for the treatment of superficial thrombophlebitis. ( Aston, CE; Rathbun, SW; Whitsett, TL, 2012)
" We describe a female patient, whose localized reaction from dalteparin was followed by a generalized rash presenting as acute generalized exanthematous pustulosis."	7.74	Acute generalized exanthematous pustulosis from dalteparin. ( Aberer, W; Grims, R; Komericki, P; Kränke, B, 2007)
"Dalteparin is superior to the NSAID ibuprofen in preventing extension of superficial thrombophlebitis during the 14-day treatment period with similar relief of pain and no increase in bleeding."	5.16	A randomized trial of dalteparin compared with ibuprofen for the treatment of superficial thrombophlebitis. ( Aston, CE; Rathbun, SW; Whitsett, TL, 2012)
"We compared enoxaparin and adjusted-dose warfarin with respect to their safety and their efficacy in the prevention of clinically important venous thromboembolic disease, defined as distal or proximal deep venous thrombosis or pulmonary embolism, or both, during hospitalization after total hip arthroplasty."	5.09	Comparison of enoxaparin and warfarin for the prevention of venous thromboembolic disease after total hip arthroplasty. Evaluation during hospitalization and three months after discharge. ( Bigler, GT; Collis, DK; Colwell, CW; Hardwick, ME; Lutz, S; McCutchen, JW; Paulson, R, 1999)
"Dalteparin is an LMWH indicated for patients undergoing abdominal surgery who are considered to be at risk for deep-vein thrombosis (DVT), which may lead to pulmonary embolism (PE)."	4.79	Dalteparin: a low-molecular-weight heparin. ( Howard, PA, 1997)
"The risk of late thrombosis and pulmonary embolism is discussed from pathogenetic factors and data on frequencies of thromboembolic complications in the literature."	3.78	Prolonged prophylaxis against postoperative venous thromboembolism. ( Bergqvist, D, 1996)
" We describe a female patient, whose localized reaction from dalteparin was followed by a generalized rash presenting as acute generalized exanthematous pustulosis."	3.74	Acute generalized exanthematous pustulosis from dalteparin. ( Aberer, W; Grims, R; Komericki, P; Kränke, B, 2007)
"5 mg/kg subcutaneous is at least as effective and safe as conventional treatment with a continuous intravenous infusion of UFH."	2.71	An open-label, comparative study of the efficacy and safety of once-daily dose of enoxaparin versus unfractionated heparin in the treatment of proximal lower limb deep-vein thrombosis. ( Araújo, GR; Dietrich-Neto, F; Karaoglan de Moura, L; Lastoria, S; Maffei, FH; Michaelis, W; Ramacciotti, E; Sandri, JL, 2004)
" However, different LMWHs vary significantly in their pharmacokinetic profile and bioavailability pattern."	2.70	[Prospective randomized study comparing the effectiveness and tolerance of various low-molecular-weight heparins in high risk patients]. ( Bergauer, F; Hagena, FW; Janni, W; Lohscheidt, K; Rjosk, D, 2001)
" The present study investigates if the physiological deterioration of renal function associated with normal aging or the presence of an acute venous thromboembolism influences the pharmacodynamic pattern of the anti-factor Xa and anti-thrombin activities."	2.69	Aging and venous thromboembolism influence the pharmacodynamics of the anti-factor Xa and anti-thrombin activities of a low molecular weight heparin (nadroparin). ( Boneu, B; d'Azemar, P; Decousus, H; Duret, JP; Gaud, C; Laporte-Simitsidis, S; Mismetti, P; Navarro, C; Necciari, J; Sié, P, 1998)
"1 respectively); 2) On day 10, the AUC(0-12 h) were slightly but significantly lower than the AUC(12-24 h) suggesting a circadian effect for anti-Xa and anti-IIa activities; 3) the clearance of the anti-Xa activity was comparable at the 2-dose regimens, while that of the anti-IIa activity was lower in treatment B than in treatment A, indicating a significant dose effect for the pharmacodynamics of the longer heparin chains; 4) On average, the clearance of the anti-IIa activity was twice as high as that of the anti-Xa activity; 5) For treatment B, significant APTT prolongations were noticed at Tmax (prolongation factor: 1."	2.69	Pharmacodynamics and tolerance of two nadroparin formulations (10,250 and 20,500 anti Xa IU x ml(-1)) delivered for 10 days at therapeutic dose. ( Boneu, B; Cambus, JP; Caplain, H; d'Azemar, P; Duret, JP; Gaud, C; Navarro, C; Necciari, J; Sié, P, 1998)
" Regardless of the dosage designation (mg/kg or units/kg) each LMWH followed a distinct TFPI release profile."	2.68	The role of tissue factor pathway inhibitor in the mediation of the antithrombotic actions of heparin and low-molecular-weight heparin. ( Bermes, EW; Fareed, J; Hoppensteadt, DA; Jeske, W, 1995)
"In a multicentre, randomized, double-blind controlled trial comparing the low-molecular-weight heparin enoxaparin (40 mg) with a standard unfractionated heparin (Ca-heparin, 3 x 5,000 U) in deep-vein thrombosis prophylaxis in a high-risk group of 959 hospitalized medical patients, enoxaparin was at least as efficacious as standard heparin, with fewer adverse events."	2.68	The venous thrombotic risk in non-surgical patients: epidemiological data and efficacy/safety profile of a low-molecular-weight heparin (enoxaparin). The Prime Study Group. ( Flosbach, CW; Lechler, E; Schramm, W, 1996)
" A uniform dosage of 2 mg/kg/day in two divided doses was administered subcutaneously for 10 days during hospitalization and then continued on an out-patient basis."	2.68	Low molecular heparin (Enoxaparin) as an alternative treatment of acute deep venous thrombosis in gynecologic oncology patients. ( Altaras, M; Aviram, R; Beyth, Y; Fishman, A; Klein, Z, 1996)
"Bleeding was determined according to pre-defined objective criteria for major and minor episodes."	2.68	Low molecular weight heparin and compression stockings in the prevention of venous thromboembolism in neurosurgery. ( Büller, HR; d'Azemar, P; Gent, M; Haley, S; Henkens, CM; Hoek, JA; Koopman, MM; Nurmohamed, MT; Que, GT; Sicurella, A; ten Cate, JW; Turpie, AG; van der Heul, C; van der Meer, J; van Riel, AM, 1996)
"Distal and proximal thrombosis, pulmonary embolism, and hemorrhage were also recorded, as were deaths."	2.68	Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement. ( Benoni, G; Bergqvist, D; Björgell, O; Fredin, H; Hedlundh, U; Nicolas, S; Nilsson, P; Nylander, G, 1996)
" Safety outcomes were defined as the occurrence of major and minor haemorrhage, other adverse events and changes in laboratory parameters."	2.68	Efficacy and safety of postdischarge administration of enoxaparin in the prevention of deep venous thrombosis after total hip replacement. A prospective randomised double-blind placebo-controlled trial. ( Bellaud, M; Compan, D; Darmon, JY; Fagola, M; Huet, Y; Planes, A; Saliba, E; Vochelle, N; Weisslinger, N, 1996)
"Enoxaparin, 40 mg once daily, is as safe and effective as unfractionated heparin three times daily in preventing venous thromboembolism in patients undergoing major elective surgery for abdominal or pelvic malignancy."	2.68	Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: a double-blind randomized multicentre trial with venographic assessment. ENOXACAN Study Group. ( , 1997)
"However, its application to pulmonary embolism or previous episodes of thromboembolism has not been studied."	2.68	Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. ( Baildon, R; Büller, HR; Gallus, AS; Gent, M; Ginsberg, J; Prins, MH, 1997)
" According to our experience, Fragmin at the dosage used proved to be both effective and safe in these patients."	2.68	Upper extremity deep venous thrombosis in cancer patients with venous access devices--prophylaxis with a low molecular weight heparin (Fragmin). ( Abad, A; Alastrue, A; Mira, X; Monreal, M; Muxart, J; Rosell, R; Rull, M, 1996)
"Bleeding was assessed on the basis of intraoperative blood loss, transfusion requirements, a decrease in hematocrit, and clinically identified bleeding complications."	2.68	Prevention of deep-vein thrombosis after total hip arthroplasty. Comparison of warfarin and dalteparin. ( Ayers, DC; Boyd, AD; Francis, CW; Johanson, NA; Kessler, C; Liebert, KM; Marder, VJ; Pellegrini, VD; Rosenberg, A; Stulberg, BN; Totterman, S, 1997)
" This study showed that Enoxaparin administered postoperatively 30 mg every 12 hours is more effective and as safe as unfractionated heparin prophylaxis to prevent deep venous thrombosis in patients having elective total knee arthroplasty."	2.68	Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep venous thrombosis after elective knee arthroplasty. Enoxaparin Clinical Trial Group. ( Colwell, CW; Gardiner, GA; Ritter, MA; Spiro, TE; Stephens, JW; Trowbridge, AA, 1995)
"There was only one pulmonary embolism (PE) in a patient belonging to UH-group (1."	2.68	Low molecular weight heparin (enoxaparin) compared with unfractionated heparin in prophylaxis of deep venous thrombosis and pulmonary embolism in patients undergoing hip replacement. ( Avikainen, V; Hakkinen, S; Kaaja, R; Kaira, P; Partio, E; Usenius, JP; von Bonsdorff, H, 1995)
" The target antithrombotic aXa levels, determined by amidolytic assay in plasma 6 hours after each ardeparin injection, were most optimally attained and maintained by twice-daily dosing based on body weight and correlated well with incremental increases in Heptest values measured chronometrically."	2.68	Monitoring the anticoagulant effects of a low molecular weight heparin preparation. Correlation of assays in orthopedic surgery patients receiving ardeparin sodium for prophylaxis of deep venous thrombosis. ( Davidson, BL; Druy, E; Esparraguera, IM; Fortune, WP; Giordano, J; Holloway, DS; Jacobs, HM; Kessler, CM, 1995)
"The naproxen was given orally (500 mg as a single daily dose, n = 39)."	2.67	[Therapeutic management of superficial venous thrombosis with calcium nadroparin. Dosage testing and comparison with a non-steroidal anti-inflammatory agent]. ( Auger, D; Grange, P; Hecquet, JP; Remond, A; Titon, JP; Ulliac, P; Vaissié, JJ, 1994)
"To determine the most effective and safe dose of enoxaparin to prevent deep venous thrombosis in high-risk surgical patients."	2.67	Efficacy and safety of enoxaparin to prevent deep venous thrombosis after hip replacement surgery. Enoxaparin Clinical Trial Group. ( Blasier, RB; Christie, MJ; Johnson, GJ; Lyons, RM; MacFarlane, DE; Spiro, TE; Tremaine, MD, 1994)
"The incidence of DVT and of pulmonary embolism was 4."	2.67	An international multicentre study: Clivarin in the prevention of venous thromboembolism in patients undergoing general surgery. Report of the International Clivarin Assessment Group. ( Boneu, B, 1993)
"Of these 14 late recurrences, just one occurred in patients with postoperative DVT."	2.67	Low molecular weight heparin versus warfarin in the prevention of recurrences after deep vein thrombosis. ( Aiello, S; Dettori, AG; Manotti, C; Pattacini, C; Pini, M; Poli, T; Quintavalla, R; Tagliaferri, A, 1994)
" Excessive bleeding, on the basis of specified criteria, severe adverse effects, or occurrence of clinically detected venous thromboembolism was classified as failure."	2.67	Safety of enoxaparin and dextran-70 in the prevention of venous thromboembolism in digestive surgery. A play-the-winner-designed study. ( Andersen, OK; Larsen, S; Lund, H; Løvig, T; Mowinckel, P; Reiertsen, O; Størkson, R; Trondsen, E, 1993)
" In a prospective randomized trial involving 122 consecutive patients, group A (58 patients) received a weight adjusted dose of Fragmin (100 IU/kg) subcutaneously twice a day throughout the treatment period (10 days +/- 1), while in group B (64 patients) the dosage was based on the results of an anti factor Xa (anti Xa) amidolytic assay to obtain a target concentration from 0."	2.67	Adjusted versus fixed doses of the low-molecular-weight heparin fragmin in the treatment of deep vein thrombosis. Fragmin-Study Group. ( Aiach, M; Alhenc-Gelas, M; Fiessinger, JN; Jestin-Le Guernic, C; Kher, A; Vitoux, JF, 1994)
"It presents as an acute spinal cord compression and usually requires emergency surgical decompression."	2.48	[Spontaneous resolution of a paraparesis due to a dorsolumbar epidural haematoma associated with subarachnoid anaesthesia and postoperative analgesia using an epidural catheter]. ( Alemán Martín, A; Coronado Hijón, V; Jiménez Delgado, P; Sánchez Gutiérrez, C, 2012)
"Lemierre's syndrome is a potentially fatal disease that usually presents with oropharyngeal infection, followed by sepsis, thrombosis of the internal jugular vein and septic emboli."	2.45	Unusual presentation of Lemierre's syndrome: two cases and a review. ( Brandjes, DP; Gerdes, VE; Soesan, M; van Gorp, EC; van Wissen, M, 2009)
" The dosage of LMWH was performed by body weight adjustment without dose-finding studies."	2.42	[Treatment of thrombosis with low-molecular-weight heparin. Comparison of body weight-adjusted and fixed dosage]. ( Harenberg, J, 2003)
" Further clinical trials are required to test different dosage regimens as a thromboprophylactic agent in high risk patients."	2.39	Patients at risk of venous thromboembolism--clinical results with reviparin. ( Cohen, AT; Kakkar, VV; Mohamed, MS, 1996)
" In comparative clinical trials, this dosage demonstrated either improved efficacy and a similar haemorrhagic profile, or a similar degree of efficacy with a lower rate of haemorrhagic events, compared with unfractionated heparin 5000IU 3 times daily."	2.39	Enoxaparin. A reappraisal of its pharmacology and clinical applications in the prevention and treatment of thromboembolic disease. ( Goa, KL; Noble, S; Peters, DH, 1995)
"Four trials of enoxaparin (involving 567 patients) and six trials of warfarin (involving 630) met the following criteria: randomized controlled trial, prophylaxis started no later than 24 hours after surgery and continued for at least 7 days, warfarin dose monitored and adjusted appropriately, enoxaparin dosage 30 mg twice daily, and DVT confirmed by bilateral venography."	2.39	Cost-effectiveness of enoxaparin versus warfarin prophylaxis against deep-vein thrombosis after total hip replacement. ( Anderson, DR; Goeree, R; O'Brien, BJ, 1994)
"5 kD, has greater bioavailability and a longer duration of action than unfractionated heparin, allowing it to be administered once daily by subcutaneous injection for both prophylaxis and treatment of deep venous thrombosis (DVT)."	2.39	Tinzaparin. A review of its pharmacology and clinical potential in the prevention and treatment of thromboembolic disorders. ( Balfour, JA; Friedel, HA, 1994)
"Dalteparin and logiparin were effective when administered in single daily subcutaneous doses; this could lead to lower treatment costs."	2.38	Low-molecular-weight heparins for the treatment of deep-vein thrombosis. ( Cziraky, MJ; Spinler, SA, 1993)
"Cerebral thrombophlebitis is a rare but severe disease whose underestimated frequency is increasingly recognized among children and, unlike adults, management is controversial."	1.56	[Cerebral thrombophlebitis: complication of frontotemporoparietal cellulitis in a child victim of human bite]. ( Aabdi, M; Badsi, S; Diyas, S; Housni, B, 2020)
" We administered body-weight adjusted full dose of low-molecular weight heparin (enoxaparin) in a therapeutic dosage for 10 days."	1.42	Penile Mondor's syndrome after endovenous treatment of the great saphenous vein with 1470 nm diode laser. ( Knittel, M; Schwarz, T; Zeller, T; Zerweck, C, 2015)
"Facial vein thrombophlebitis is an uncommon complication of sinusitis."	1.42	Facial vein thrombophlebitis: an uncommon complication of sinusitis. ( Cotes, C; Riascos, R; Swischuk, LE, 2015)
"Acute pulmonary embolism is an important emergency disease which frequently results in life-threatening complication."	1.39	Effectiveness of low-dose prolonged infusion of tissue plasminogen activator in a nonagenarian patient with acute pulmonary embolism and main pulmonary artery thrombus. ( Acar, RD; Karakoyun, S; Ozkan, M; Yildiz, M, 2013)
"Given that deep vein thrombosis coincided with obstetric delivery, it was crucial to decide on anesthetic and therapeutic approaches that would assure maternal and fetal safety and prevent such complications as massive pulmonary thromboembolism."	1.36	[Parturient at full term with inferior vena cava thrombosis: anesthesia during surgical delivery]. ( Amorós, B; Bermejo, L; Dueñas, N; Fernández, E; Perea, M; Villafranca, A, 2010)
"The cumulative rate of unprovoked recurrence in patients with a positive D-dimer was 20% at 5 years [5."	1.35	Unprovoked recurrent venous thrombosis: prediction by D-dimer and clinical risk factors. ( Baglin, C; Baglin, T; Luddington, R; Palmer, CR, 2008)
"A 43-year-old white woman with adult respiratory distress syndrome developed localized dermal necrosis and thrombocytopenia secondary to subcutaneous administration of unfractionated heparin."	1.30	Enoxaparin-associated dermal necrosis: a consequence of cross-reactivity with heparin-mediated antibodies. ( Kollef, MH; Schaiff, RA; Tonn, ME, 1997)
" The mean time for dosage increase was 20."	1.30	Thromboprophylaxis with low molecular weight heparin (Fragmin) in high risk pregnancies. ( Buchanan, N; Copplestone, A; Doughty, HA; Hughes, G; Hunt, BJ; Kerslake, S; Khamashta, M; Majumdar, G, 1997)
"No deep venous thrombosis and no pulmonary embolism were observed."	1.29	[General perioperative prevention of thromboembolism in gynecology with low-molecular weight heparin: clinical experiences with enoxaparin over 7 years]. ( Slunsky, R, 1995)

Research

Studies (176)

Authors

Clinical Trials (11)

Trial Overview

Trial Outcomes

Peak Venous Velocity

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	125 (71.02)	18.2507
2000's	34 (19.32)	29.6817
2010's	14 (7.95)	24.3611
2020's	3 (1.70)	2.80

Authors	Studies
van Wissen, M	1
Gerdes, VE	1
van Gorp, EC	1
Brandjes, DP	1
Soesan, M	1
Camporese, G	1
Bernardi, E	1
Noventa, F	1
Hoppensteadt, DA	2
Jeske, W	1
Fareed, J	2
Bermes, EW	1
Peyrou, V	1
Lormeau, JC	1
Caranobe, C	1
Gabaig, AM	1
Crepon, B	1
Saivin, S	1
Houin, G	1
Sié, P	3
Boneu, B	6
Teo, CP	1
Lim, HL	1
Kueh, YK	1
Titon, JP	1
Auger, D	1
Grange, P	1
Hecquet, JP	1
Remond, A	1
Ulliac, P	1
Vaissié, JJ	1
Pistorius, MA	1
Said, L	1
Planchon, B	1
Cziraky, MJ	1
Spinler, SA	1
Mironov, SP	1
Burmakova, GM	1
Fedotova, TM	1
Diquélou, A	1
Dupouy, D	1
Cariou, R	1
Sakariassen, KS	1
Cadroy, Y	1
Schain, FH	1
Nurmohamed, MT	1
van Riel, AM	1
Henkens, CM	1
Koopman, MM	1
Que, GT	1
d'Azemar, P	4
Büller, HR	3
ten Cate, JW	1
Hoek, JA	1
van der Meer, J	1
van der Heul, C	1
Turpie, AG	1
Haley, S	1
Sicurella, A	1
Gent, M	4
Haentjens, P	1
Hirsh, J	3
Tomkowski, W	1
Borowiec, B	1
Burakowski, J	1
Hajduk, B	1
Filipecki, S	2
Czestochowska, E	2
Grau Segura, E	1
Real Vila, E	1
Pastor Guzmán, E	1
Torró Richart, JA	1
Garay Burdeos, M	1
Züger, M	1
Demarmels Biasiutti, F	2
Wuillemin, WA	2
Furlan, M	1
Lämmle, B	2
Szücs, G	1
Mikó, I	1
Ajzner, E	1
Póti, L	1
Szepesi, K	1
Furka, I	1
Navarro, C	2
Cambus, JP	1
Caplain, H	1
Necciari, J	2
Duret, JP	2
Gaud, C	2
Charbonnier, BA	1
Fiessinger, JN	3
Banga, JD	1
Wenzel, E	2
Sagnard, L	1
Mismetti, P	1
Laporte-Simitsidis, S	1
Decousus, H	2
Mauron, T	1
Baumgartner, I	1
Z'Brun, A	1
Redondo, M	1
Do, DD	1
Lopaciuk, S	1
Bielska-Falda, H	1
Noszczyk, W	1
Bielawiec, M	1
Witkiewicz, W	1
Michalak, J	1
Ciesielski, L	1
Mackiewicz, Z	1
Zawilska, K	1
Cencora, A	1
Lloyd, A	1
Aitken, JA	1
Hoffmeyer, UK	1
Kelso, EJ	1
Wakerly, EC	1
Barber, ND	1
Stricker, H	1
Marchetti, O	1
Haeberli, A	1
Mombelli, G	1
Goldberg, A	1
López-Beret , P	1
Orgaz, A	1
Fontcuberta, J	1
Doblas, M	1
Martinez, A	1
Lozano, G	1
Romero, A	1
Cherenkov, AA	1
Shishkin, SA	1
Nekrasov, AI	1
Beghi, C	1
Fragnito, C	1
Antonelli, A	1
Reverberi, C	1
Ferrari, P	1
Saccani, S	1
Fesani, F	1
Haas, S	4
Breddin, HK	2
Badsi, S	1
Diyas, S	1
Aabdi, M	1
Housni, B	1
Kewan, T	1
Almhana, F	1
Schwartzman, L	1
Daw, H	1
Haddad, A	1
Özbek, DA	1
Bilgin, E	1
Onur, MR	1
Karadağ, Ö	1
Kiraz, S	1
Martín Guerra, JM	1
Asenjo, MM	1
Dueñas Gutiérrez, CJ	1
Gil González, I	1
Zerweck, C	1
Knittel, M	1
Zeller, T	1
Schwarz, T	1
De Maddi, F	1
Sottile, R	1
Andreozzi, L	1
Rigante, D	1
Patel, N	1
Singhal, D	1
Cotes, C	1
Riascos, R	1
Swischuk, LE	1
Alhadad, A	1
Acosta, S	1
Sarabi, L	1
Kölbel, T	1
Fernández, E	1
Dueñas, N	1
Villafranca, A	1
Perea, M	1
Amorós, B	1
Bermejo, L	1
Karow, A	1
Hainmann, I	1
Nakamura, L	1
Budde, U	1
Mueller, C	1
Zieger, B	1
Lauretta, A	1
Almoudaris, AM	1
Jiao, LR	1
Sánchez Gutiérrez, C	1
Alemán Martín, A	1
Coronado Hijón, V	1
Jiménez Delgado, P	1
Yildiz, M	1
Karakoyun, S	1
Acar, RD	1
Ozkan, M	1
Cohen, AT	4
Ramacciotti, E	1
Araújo, GR	1
Lastoria, S	1
Maffei, FH	1
Karaoglan de Moura, L	1
Michaelis, W	1
Sandri, JL	1
Dietrich-Neto, F	1
Alli, NA	1
Wainwright, RD	1
Mackinnon, D	1
Poyiadjis, S	1
Naidu, G	1
Evanchuk, DM	1
Von Gehr, A	1
Zehnder, JL	1
Baglin, T	1
Palmer, CR	1
Luddington, R	1
Baglin, C	1
Fitzgerald, RH	1
Colwell, CW	4
Spiro, TE	4
Trowbridge, AA	2
Stephens, JW	1
Gardiner, GA	1
Ritter, MA	1
Reiertsen, O	2
Larsen, S	2
Størkson, R	1
Trondsen, E	1
Løvig, T	2
Andersen, OK	1
Lund, H	1
Mowinckel, P	2
Verhaeghe, R	1
Flosbach, CW	2
Avikainen, V	1
von Bonsdorff, H	1
Partio, E	1
Kaira, P	1
Hakkinen, S	1
Usenius, JP	1
Kaaja, R	1
Warkentin, TE	1
Levine, MN	1
Horsewood, P	1
Roberts, RS	1
Kelton, JG	1
Noble, S	1
Peters, DH	1
Goa, KL	1
Saltiel, E	1
Saya, F	1
Drummond, M	1
Aristides, M	1
Davies, L	1
Forbes, C	1
Pini, M	2
Aiello, S	1
Manotti, C	1
Pattacini, C	1
Quintavalla, R	1
Poli, T	1
Tagliaferri, A	1
Dettori, AG	1
Johnson, GJ	1
Christie, MJ	1
Lyons, RM	1
MacFarlane, DE	1
Blasier, RB	1
Tremaine, MD	1
Pham, J	1
Montefiore, A	1
Deschamps, A	1
O'Brien, BJ	1
Anderson, DR	2
Goeree, R	1
Menzin, J	1
Richner, R	1
Huse, D	1
Colditz, GA	1
Oster, G	1
Carter, CA	1
Skoutakis, VA	2
West, ME	1
Tooms, RE	1
Joe, RH	1
Knutson, TJ	1
Morris, BA	1
Kwaan, HC	1
Blaha, JD	1
Comerota, AJ	1
Farkas, JC	1
Chapuis, C	1
Combe, S	1
Silsiguen, M	1
Marzelle, J	1
Laurian, C	1
Cormier, JM	1
Slunsky, R	1
Planes, A	6
Vochelle, N	5
Darmon, JY	3
Fagola, M	3
Bellaud, M	3
Huet, Y	3
Bergqvist, D	4
Benoni, G	1
Björgell, O	1
Fredin, H	1
Hedlundh, U	1
Nicolas, S	1
Nilsson, P	1
Nylander, G	1
Lechler, E	1
Schramm, W	1
Bjerkeseth, O	1
Thorsen, G	1
Gerner, T	1
Løtveit, T	1
Atkins, CD	1
Bergmann, JF	1
Neuhart, E	1
Fishman, A	1
Altaras, M	1
Klein, Z	1
Aviram, R	1
Beyth, Y	1
Basskin, L	1
Jacobson, M	1
Perhoniemi, V	1
Vuorinen, J	1
Myllynen, P	1
Kivioja, A	1
Lindevall, K	1
Gross, M	1
Robinson, KS	1
Wells, PS	1
Compan, D	1
Saliba, E	1
Weisslinger, N	1
Tonn, ME	1
Schaiff, RA	1
Kollef, MH	1
Gallay, S	1
Waddell, JP	1
Cardella, P	1
Morton, J	1
Hawkins, DW	1
Langley, PC	1
Krueger, KP	1
Manktelow, AR	1
Haddad, FS	1
Powles, DP	1
Dedden, P	1
Chang, B	1
Nagel, D	1
Eskander, MB	1
Limb, D	1
Stone, MH	1
Furlong, AJ	1
Shardlow, D	1
Stead, D	1
Culleton, G	1
Eriksson, BI	3
Wille-Jørgensen, P	4
Kälebo, P	2
Mouret, P	1
Rosencher, N	1
Bösch, P	1
Baur, M	1
Ekman, S	1
Bach, D	1
Lindbratt, S	1
Close, P	1
Ewenstein, BM	1
Ellis, MH	1
Nun, IB	1
Rathaus, V	1
Werner, M	1
Shenkman, L	1
Leizorovicz, A	1
Parent, F	1
Page, Y	1
Tardy, B	1
Girard, P	1
Laporte, S	1
Faivre, R	1
Charbonnier, B	1
Barral, FG	1
Simonneau, G	1
Kévorkian, JP	1
Halimi, C	1
Segrestaa, JM	1
Drouet, L	1
Soria, C	1
Robb, J	1
Garcia-Zozaya, I	1
Finkelstein, Y	1
Aloni, D	1
Kimia, A	1
Sommer, R	1
Sirota, L	1
Agnelli, G	1
Piovella, F	1
Buoncristiani, P	1
Severi, P	1
D'Angelo, A	1
Beltrametti, C	1
Damiani, M	1
Andrioli, GC	1
Pugliese, R	1
Iorio, A	1
Brambilla, G	1
Leclerc, JR	1
Geerts, WH	1
Ginsberg, JS	1
Davidson, BL	2
Dickinson, LD	1
Miller, LD	1
Patel, CP	1
Gupta, SK	1
Saunders, ME	1
Grant, RE	1
Tomaio, A	1
Kirshblum, SC	1
O'Connor, KC	1
Johnston, M	1
Samama, MM	2
Lensing, AW	1
Barre, J	1
Beau, B	1
Collis, DK	1
Paulson, R	1
McCutchen, JW	1
Bigler, GT	1
Lutz, S	1
Hardwick, ME	1
Gonzalez-Fajardo, JA	1
Arreba, E	1
Castrodeza, J	1
Perez, JL	1
Fernandez, L	1
Agundez, I	1
Mateo, AM	1
Carrera, S	1
Gutiérrez, V	1
Vaquero, C	1
Mahé, I	1
Veiga, F	1
Escribá, A	1
Maluenda, MP	1
López Rubio, M	1
Margalet, I	1
Lezana, A	1
Gallego, J	1
Ribera, JM	1
Gilbert, KB	1
Rodgers, GM	1
Magdelaine, A	1
Verdy, E	1
Coulet, F	1
Berkane, N	1
Girot, R	1
Uzan, S	1
Soubrier, F	1
Szczesny, G	1
Deszczyński, J	1
Janni, W	1
Bergauer, F	1
Rjosk, D	1
Lohscheidt, K	1
Hagena, FW	1
Gallus, AS	2
Jönsson, B	1
Marietta, M	1
Bertesi, M	1
Simoni, L	1
Castelli, I	1
Cappi, C	1
Torelli, G	1
Feret, J	1
Kadziola, Z	1
Scully, M	1
Nakov, R	1
Misselwitz, F	1
Kakkar, VV	3
Mohamed, MS	1
Boeckl, O	1
Bordenave, L	1
Brehm, OA	1
Brücke, P	1
Coccheri, S	1
Galland, F	1
Jarrige, J	1
Koppenhagen, K	1
LeQuerrec, A	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Hemodynamic Comparison of Stationary and Portable Pneumatic Compression Devices[NCT02345642]		20 participants (Actual)	Interventional	2015-02-28	Completed
Extended Out-of-hospital Low-molecular-weight Heparin Prophylaxis Against Deep Venous Thrombosis and Pulmonary Embolus in Patients Undergoing Major Lung Resection: A Pilot Study to Evaluate the Incidence of DVT and PE After Major Lung Resection[NCT02258958]		150 participants (Actual)	Observational	2014-01-31	Completed
Effect of Anticoagulation in Reducing the Incidence of Splenic/Portal Vein Thrombosis Post-Laparoscopic Splenectomy Protocol Number: 5698[NCT00769873]	Phase 2	35 participants (Actual)	Interventional	2006-10-31	Terminated (stopped due to Recruitment was slower than anticipated. Insufficient funding to expand to multi-centered trial.)
PREPIC 2 : Interruption of Inferior Vena Cava by a Retrievable Filter for the Prevention of Recurrent Pulmonary Embolism : a Randomised, Open Label Study[NCT00457158]	Phase 4	399 participants (Actual)	Interventional	2006-07-31	Completed
Retrievable Inferior Vena Cava Filter for Primary Pulmonary Embolism Prophylaxis in At-Risk Trauma Patients: RIPT Feasibility Trial[NCT03070834]		42 participants (Actual)	Interventional	2017-07-01	Completed
Phase 1 Study in Humans Evaluating the Safety of Rectus Sheath Implantation of Diffusion Chambers Encapsulating Autologous Malignant Glioma Cells Treated With Insulin-Like Growth Factor Receptor-1 Antisense Oligodeoxynucleotide in 12 Patients With Recurre[NCT01550523]	Phase 1	13 participants (Actual)	Interventional	2012-02-09	Completed
Norwegian Intensive Care Unit Dalteparin Effect Study[NCT01721928]		70 participants (Actual)	Observational	2012-12-03	Completed
A Double Blind Randomized Control Trial of Post-Operative Low Molecular Weight Heparin Bridging Therapy Versus Placebo Bridging Therapy for Patients Who Are at High Risk for Arterial Thromboembolism (PERIOP 2)[NCT00432796]	Phase 3	1,473 participants (Actual)	Interventional	2006-12-31	Active, not recruiting
Management of Superficial Thrombophlebitis[NCT00264381]	Phase 4	72 participants (Actual)	Interventional	2002-10-31	Completed
Evaluation of the Efficacy of Elastic Compression in Preventing Post-thrombotic Syndrome. Randomised Non-inferiority Study for Ankle Pressure Targeted at 25 mm Hg Versus 35 mm Hg[NCT01578122]		350 participants (Actual)	Interventional	2012-06-29	Completed
Intensive Dose Tinzaparin in Hospitalized COVID19 Patients[NCT05036824]		300 participants (Anticipated)	Observational	2021-10-01	Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Ultrasound of the venous system just below the saphenofemoral junction to assess the venous velocity will be taken before and after application the VenaFlow and the ActiveCare+S.F.T pneumatic compression devices. Change from Baseline in Peak Venous Velocity 30 minutes after Device is applied is recorded. (NCT02345642)
Timeframe: Change from Baseline in Peak Venous Velocity 30 minutes after Device is Applied

Change From Baseline to Day 14 in Pain Assessment

Intervention	cm/s (Mean)
	Delta PVV from before to after Venaflow (Standing)	Delta PVV from before to after Venaflow (Supine)	delta PVV from before to after Activeca (Standing)	delta PVV from before to after Activecare (supine)
10 Healthy Patients Without THA	127.9	87.1	32.6	40.5
10 Patients With THA on Post-Op Day 2	155.7	86.8	41.9	37.8

Change in pain at day 14 as measured by 11-point Box Pain Scale, 0 being the least amount of pain, and 10 the most amount of pain (NCT00264381)
Timeframe: Day 1, Day 14

Major and Minor Bleeding Secondary to Dalteparin and Ibuprofen Treatment During the 3 Month Follow up.

Intervention	units on a scale (Mean)
Ibuprofen 800 mg Tid	-2.28
Dalteparin 200 U/kg Then 10,000 U Daily	-2.23

Number of participants with bleeding events related to treatment (NCT00264381)
Timeframe: 3 months

Thrombosis Progression and Venous Thromboembolism (VTE)

Intervention	participants (Number)
Ibuprofen 800 mg Tid	0
Dalteparin 200 U/kg Then 10,000 U Daily	0

Thrombosis progression and deep vein thrombosis at day 14 by ultrasound testing (NCT00264381)
Timeframe: Day 14

Thrombosis Progression or Venous Thromboembolism (VTE) at 3 Months

Intervention	participants (Number)
	Thrombosis progression	VTE
Dalteparin 200 U/kg Then 10,000 U Daily	0	0
Ibuprofen 800 mg Tid	4	0

Symptomatic thrombosis extension (DVT) or pulmonary embolism at 3 months documented by radiologic testing. (NCT00264381)
Timeframe: 3 months

Article	Year
Unusual presentation of Lemierre's syndrome: two cases and a review. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2009, Volume: 20, Issue:6 Topics: Acenocoumarol; Anti-Bacterial Agents; Anticoagulants; Bacteremia; Deglutition Disorders; Diarrhea; F	2009
[Prevention of deep venous thrombosis after knee arthroscopy. Recent advances]. Recenti progressi in medicina, 2009, Volume: 100, Issue:5 Topics: Anticoagulants; Arthroscopy; Combined Modality Therapy; Follow-Up Studies; Hemorrhage; Humans; Incid	2009
Low-molecular-weight heparins for the treatment of deep-vein thrombosis. Clinical pharmacy, 1993, Volume: 12, Issue:12 Topics: Clinical Trials as Topic; Dalteparin; Enoxaparin; Heparin, Low-Molecular-Weight; Humans; Nadroparin;	1993
Comparison of the relative efficacy and safety of low molecular weight heparin and unfractionated heparin for the treatment of venous thrombosis. Haemostasis, 1996, Volume: 26 Suppl 4 Topics: Adult; Anticoagulants; Double-Blind Method; Enoxaparin; Fibrinolytic Agents; Hemorrhage; Heparin; He	1996
[Spontaneous resolution of a paraparesis due to a dorsolumbar epidural haematoma associated with subarachnoid anaesthesia and postoperative analgesia using an epidural catheter]. Revista espanola de anestesiologia y reanimacion, 2012, Volume: 59, Issue:9 Topics: Aged; Analgesia, Epidural; Anesthesia, Epidural; Anesthesia, Spinal; Anticoagulants; Arthroplasty, R	2012
Discoveries in thrombosis care for medical patients. Seminars in thrombosis and hemostasis, 2002, Volume: 28 Suppl 3 Topics: Clinical Trials as Topic; Cost-Benefit Analysis; Critical Care; Drug Costs; Enoxaparin; Fibrinolytic	2002
Skull bone infarctive crisis and deep vein thrombosis in homozygous sickle cell disease- case report and review of the literature. Hematology (Amsterdam, Netherlands), 2007, Volume: 12, Issue:2 Topics: Anemia, Sickle Cell; Anticoagulants; Catheterization; Child; Diagnosis, Differential; Edema; Enoxapa	2007
Enoxaparin. A reappraisal of its pharmacology and clinical applications in the prevention and treatment of thromboembolic disease. Drugs, 1995, Volume: 49, Issue:3 Topics: Biological Availability; Blood Coagulation; Dose-Response Relationship, Drug; Enoxaparin; Female; He	1995
Cost-effectiveness of enoxaparin versus warfarin prophylaxis against deep-vein thrombosis after total hip replacement. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 1994, Apr-01, Volume: 150, Issue:7 Topics: Cost-Benefit Analysis; Enoxaparin; Hip Prosthesis; Humans; Postoperative Complications; Thrombophleb	1994
Enoxaparin: the low-molecular-weight heparin for prevention of postoperative thromboembolic complications. The Annals of pharmacotherapy, 1993, Volume: 27, Issue:10 Topics: Clinical Trials as Topic; Enoxaparin; Heparin, Low-Molecular-Weight; Humans; Postoperative Complicat	1993
The role of low-molecular-weight heparins in the prevention of venous thrombosis in surgery with special reference to enoxaparin. Haemostasis, 1996, Volume: 26 Suppl 2 Topics: Dose-Response Relationship, Drug; Enoxaparin; Fibrinolytic Agents; Heparin; Humans; Meta-Analysis as	1996
Prolonged prophylaxis against postoperative venous thromboembolism. Haemostasis, 1996, Volume: 26 Suppl 4 Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Disease Susceptibility; Double-Blind Method; Drug Ad	1996
Preventing venous thromboembolism in general medical inpatients and after an ischaemic stroke. Haemostasis, 2000, Volume: 30 Suppl 2 Topics: Acute Disease; Adult; Aged; Anticoagulants; Brain Ischemia; Cerebral Hemorrhage; Clinical Trials as	2000
Patients at risk of venous thromboembolism--clinical results with reviparin. Thrombosis research, 1996, Volume: 81, Issue:2 Suppl Topics: Abdomen; Anticoagulants; Clinical Trials as Topic; Fibrinolytic Agents; Heparin, Low-Molecular-Weigh	1996
[Treatment of thrombosis with low-molecular-weight heparin. Comparison of body weight-adjusted and fixed dosage]. Medizinische Klinik (Munich, Germany : 1983), 2003, Sep-15, Volume: 98, Issue:9 Topics: Adult; Aged; Anticoagulants; Data Interpretation, Statistical; Female; Fibrinolytic Agents; Hemorrha	2003
Treatment for superficial infusion thrombophlebitis of the upper extremity. The Cochrane database of systematic reviews, 2015, Nov-20, Issue:11 Topics: Anti-Inflammatory Agents; Anticoagulants; Catheterization, Peripheral; Dalteparin; Diclofenac; Drug	2015
[Adverse cutaneous drug reactions]. Deutsche medizinische Wochenschrift (1946), 2007, Volume: 132, Issue:50 Topics: Acneiform Eruptions; Dalteparin; Diagnosis, Differential; Drug Eruptions; Eosinophilia; ErbB Recepto	2007
Dalteparin: a low-molecular-weight heparin. The Annals of pharmacotherapy, 1997, Volume: 31, Issue:2 Topics: Abdomen; Adult; Aged; Anticoagulants; Biological Availability; Dalteparin; Drug Costs; Female; Hepar	1997
Cost-effectiveness of venous thrombosis prophylaxis following ischemic stroke: an assessment of currently available literature. Thrombosis research, 1998, Feb-15, Volume: 89, Issue:4 Topics: Brain Ischemia; Chondroitin Sulfates; Clinical Trials as Topic; Cost-Benefit Analysis; Dalteparin; D	1998
Tinzaparin. A review of its pharmacology and clinical potential in the prevention and treatment of thromboembolic disorders. Drugs, 1994, Volume: 48, Issue:4 Topics: Animals; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Thromboembolism; Thrombophlebit	1994
Is there a need for long-term thromboprophylaxis following general surgery? Haemostasis, 1993, Volume: 23 Suppl 1 Topics: Bandages; Clinical Trials as Topic; Combined Modality Therapy; Double-Blind Method; Follow-Up Studie	1993

Article	Year
The role of tissue factor pathway inhibitor in the mediation of the antithrombotic actions of heparin and low-molecular-weight heparin. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 1995, Volume: 6 Suppl 1 Topics: Enoxaparin; Factor Xa Inhibitors; Heparin; Heparin, Low-Molecular-Weight; Humans; Kinetics; Lipoprot	1995
Cost effectiveness and ease of administration of low molecular weight heparin in deep vein thrombosis. Thrombosis and haemostasis, 1994, Volume: 72, Issue:2 Topics: Adult; Aged; Cost-Benefit Analysis; Female; Heparin; Humans; Injections, Subcutaneous; Male; Middle	1994
[Therapeutic management of superficial venous thrombosis with calcium nadroparin. Dosage testing and comparison with a non-steroidal anti-inflammatory agent]. Annales de cardiologie et d'angeiologie, 1994, Volume: 43, Issue:3 Topics: Adult; Aged; Ambulatory Care; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; N	1994
A comparative study of the anticoagulant and anti-thrombotic effects of unfractionated heparin and a low molecular weight heparin (Fraxiparine) in an experimental model of human venous thrombosis. Thrombosis and haemostasis, 1995, Volume: 74, Issue:5 Topics: Adolescent; Adult; Anticoagulants; Cells, Cultured; Cross-Over Studies; Endothelium, Vascular; Fibri	1995
Low molecular weight heparin and compression stockings in the prevention of venous thromboembolism in neurosurgery. Thrombosis and haemostasis, 1996, Volume: 75, Issue:2 Topics: Anticoagulants; Bandages; Combined Modality Therapy; Double-Blind Method; Hemorrhage; Humans; Nadrop	1996
Thromboembolic prophylaxis in orthopaedic trauma patients: a comparison between a fixed dose and an individually adjusted dose of a low molecular weight heparin (nadroparin calcium) Injury, 1996, Volume: 27, Issue:6 Topics: Aged; Anticoagulants; Drug Administration Schedule; Female; Hip Fractures; Humans; Leg Injuries; Mal	1996
[Clinically silent pulmonary embolism in patients with proximal deep venous thrombosis]. Pneumonologia i alergologia polska, 1996, Volume: 64 Suppl 2 Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Female; Humans; Incidence; Male; Middle Aged; Nadrop	1996
[The home treatment of deep venous thromboses with low-molecular-weight heparin]. Revista clinica espanola, 1997, Volume: 197, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Female; Fibrinolytic Agents; Follow-Up Studies; Hom	1997
Pharmacodynamics and tolerance of two nadroparin formulations (10,250 and 20,500 anti Xa IU x ml(-1)) delivered for 10 days at therapeutic dose. Thrombosis and haemostasis, 1998, Volume: 79, Issue:2 Topics: Adolescent; Adult; Anticoagulants; Chemistry, Pharmaceutical; Cross-Over Studies; Factor Xa Inhibito	1998
Comparison of a once daily with a twice daily subcutaneous low molecular weight heparin regimen in the treatment of deep vein thrombosis. FRAXODI group. Thrombosis and haemostasis, 1998, Volume: 79, Issue:5 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Female; Humans; Inj	1998
Aging and venous thromboembolism influence the pharmacodynamics of the anti-factor Xa and anti-thrombin activities of a low molecular weight heparin (nadroparin). Thrombosis and haemostasis, 1998, Volume: 79, Issue:6 Topics: Adult; Aged; Aging; Anticoagulants; Creatinine; Factor Xa Inhibitors; Female; Humans; Injections, Su	1998
Low molecular weight heparin versus acenocoumarol in the secondary prophylaxis of deep vein thrombosis. Thrombosis and haemostasis, 1999, Volume: 81, Issue:1 Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Heparin, Low-Molecular-Weight; Humans; Injectio	1999
Hemostatic activation under anticoagulant treatment: a comparison of unfractionated heparin vs. nadroparin in the treatment of proximal deep vein thrombosis. Thrombosis and haemostasis, 1999, Volume: 82, Issue:4 Topics: Adult; Aged; Anticoagulants; Female; Hemostasis; Heparin; Humans; Infusions, Intravenous; Male; Midd	1999
Low molecular weight heparin versus oral anticoagulants in the long-term treatment of deep venous thrombosis. Journal of vascular surgery, 2001, Volume: 33, Issue:1 Topics: Acenocoumarol; Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Blo	2001
Prevention of deep venous thrombosis by a new low molecular weight heparin (Fluxum) in cardiac surgery. International angiology : a journal of the International Union of Angiology, 1993, Volume: 12, Issue:4 Topics: Female; Fibrinolytic Agents; Heparin; Heparin, Low-Molecular-Weight; Humans; Male; Middle Aged; Myoc	1993
Modulation of laboratory parameters after therapeutic and prophylactic administration of Sandoparin. Seminars in thrombosis and hemostasis, 1993, Volume: 19 Suppl 1 Topics: Fibrinolysis; Heparin, Low-Molecular-Weight; Humans; Thrombophlebitis	1993
An open-label, comparative study of the efficacy and safety of once-daily dose of enoxaparin versus unfractionated heparin in the treatment of proximal lower limb deep-vein thrombosis. Thrombosis research, 2004, Volume: 114, Issue:3 Topics: Adult; Ambulatory Care; Anticoagulants; Brazil; Causality; Comorbidity; Enoxaparin; Female; Hemorrha	2004
Preventing DVT following total knee replacement: a review of recent clinical trials. Orthopedics, 1995, Volume: 18 Suppl Topics: Adult; Aged; Anticoagulants; Chemoprevention; Drug Administration Schedule; Enoxaparin; Female; Huma	1995
Consortium data: comparative efficacy of low molecular weight heparin and warfarin following total hip replacement. Orthopedics, 1995, Volume: 18 Suppl Topics: Aged; Anticoagulants; Chemoprevention; Enoxaparin; Female; Hip Prosthesis; Humans; Male; Middle Aged	1995
Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep venous thrombosis after elective knee arthroplasty. Enoxaparin Clinical Trial Group. Clinical orthopaedics and related research, 1995, Issue:321 Topics: Aged; Anticoagulants; Enoxaparin; Female; Hemorrhage; Heparin; Humans; Knee Prosthesis; Male; Thromb	1995
Safety of enoxaparin and dextran-70 in the prevention of venous thromboembolism in digestive surgery. A play-the-winner-designed study. Scandinavian journal of gastroenterology, 1993, Volume: 28, Issue:11 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Loss, Surgical; Dextrans; Digestive System Surgica	1993
Comparison of enoxaparin versus unfractionated heparin in general surgery. SURGEX-Study Group. The European journal of surgery. Supplement. : = Acta chirurgica. Supplement, 1994, Issue:571 Topics: Blood Loss, Surgical; Double-Blind Method; Enoxaparin; Hemorrhage; Hemostasis; Heparin; Humans; Post	1994
Antithromboembolic efficacy and safety of enoxaparin in general surgery. German multicentre trial. The European journal of surgery. Supplement. : = Acta chirurgica. Supplement, 1994, Issue:571 Topics: Adult; Aged; Enoxaparin; Female; Hematologic Tests; Hemorrhage; Humans; Incidence; Male; Middle Aged	1994
Low molecular weight heparin (enoxaparin) compared with unfractionated heparin in prophylaxis of deep venous thrombosis and pulmonary embolism in patients undergoing hip replacement. Annales chirurgiae et gynaecologiae, 1995, Volume: 84, Issue:1 Topics: Aged; Drug Administration Schedule; Enoxaparin; Female; Heparin; Hip Prosthesis; Humans; Male; Posto	1995
Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. The New England journal of medicine, 1995, May-18, Volume: 332, Issue:20 Topics: Confidence Intervals; Double-Blind Method; Enoxaparin; Female; Heparin; Humans; Immunoglobulin G; Od	1995
Low molecular weight heparin versus warfarin in the prevention of recurrences after deep vein thrombosis. Thrombosis and haemostasis, 1994, Volume: 72, Issue:2 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cause of Death; Enoxaparin; Female; Fibrin Fibrinogen De	1994
Efficacy and safety of enoxaparin to prevent deep venous thrombosis after hip replacement surgery. Enoxaparin Clinical Trial Group. Annals of internal medicine, 1994, Jul-15, Volume: 121, Issue:2 Topics: Aged; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hip Prosthesis; Humans;	1994
Markers of hemostatic system activation in acute deep venous thrombosis-evolution during the first days of heparin treatment. The DVTENOX Study Group. Thrombosis and haemostasis, 1993, Dec-20, Volume: 70, Issue:6 Topics: Acute Disease; Antifibrinolytic Agents; Antithrombin III; Biomarkers; Enoxaparin; Fibrin Fibrinogen	1993
Prevention of deep-vein thrombosis following total hip replacement surgery with enoxaparin versus unfractionated heparin: a pharmacoeconomic evaluation. The Annals of pharmacotherapy, 1994, Volume: 28, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Economics, Pharmaceutical; Enoxaparin; Heparin; Hip Prosthesis; Huma	1994
Use of enoxaparin, a low-molecular-weight heparin, and unfractionated heparin for the prevention of deep venous thrombosis after elective hip replacement. A clinical trial comparing efficacy and safety. Enoxaparin Clinical Trial Group. The Journal of bone and joint surgery. American volume, 1994, Volume: 76, Issue:1 Topics: Aged; Alanine Transaminase; Drug Administration Schedule; Enoxaparin; Female; Hemoglobins; Hemorrhag	1994
A randomised controlled trial of a low-molecular-weight heparin (Enoxaparin) to prevent deep-vein thrombosis in patients undergoing vascular surgery. European journal of vascular surgery, 1993, Volume: 7, Issue:5 Topics: Aged; Aorta, Abdominal; Double-Blind Method; Enoxaparin; Female; Heparin; Humans; Leg; Male; Middle	1993
Risk of deep-venous thrombosis after hospital discharge in patients having undergone total hip replacement: double-blind randomised comparison of enoxaparin versus placebo. Lancet (London, England), 1996, Jul-27, Volume: 348, Issue:9022 Topics: Aged; Anticoagulants; Double-Blind Method; Enoxaparin; Female; Hip Prosthesis; Humans; Male; Middle	1996
Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement. The New England journal of medicine, 1996, Sep-05, Volume: 335, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Drug Administration Schedule; E	1996
The venous thrombotic risk in non-surgical patients: epidemiological data and efficacy/safety profile of a low-molecular-weight heparin (enoxaparin). The Prime Study Group. Haemostasis, 1996, Volume: 26 Suppl 2 Topics: Aged; Double-Blind Method; Enoxaparin; Female; Fibrinolytic Agents; Humans; Internal Medicine; Male;	1996
Characterization of 'winners' to enoxaparin in the prevention of postoperative venous thromboembolism in digestive surgery. Scandinavian journal of gastroenterology, 1996, Volume: 31, Issue:6 Topics: Anticoagulants; Dextrans; Digestive System Surgical Procedures; Discriminant Analysis; Enoxaparin; F	1996
A multicenter randomized double-blind study of enoxaparin compared with unfractionated heparin in the prevention of venous thromboembolic disease in elderly in-patients bedridden for an acute medical illness. The Enoxaparin in Medicine Study Group. Thrombosis and haemostasis, 1996, Volume: 76, Issue:4 Topics: Acute Disease; Aged; Aged, 80 and over; Anticoagulants; Chi-Square Distribution; Double-Blind Method	1996
Low molecular heparin (Enoxaparin) as an alternative treatment of acute deep venous thrombosis in gynecologic oncology patients. European journal of gynaecological oncology, 1996, Volume: 17, Issue:5 Topics: Adult; Aged; Anticoagulants; Drug Administration Schedule; Enoxaparin; Female; Genital Neoplasms, Fe	1996
Prolonged prophylaxis against postoperative venous thromboembolism. Haemostasis, 1996, Volume: 26 Suppl 4 Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Disease Susceptibility; Double-Blind Method; Drug Ad	1996
The effect of enoxaparin in prevention of deep venous thrombosis in hip and knee surgery--a comparison with the dihydroergotamine-heparin combination. Annales chirurgiae et gynaecologiae, 1996, Volume: 85, Issue:4 Topics: Adult; Aged; Anticoagulants; Dihydroergotamine; Double-Blind Method; Drug Combinations; Drug Therapy	1996
Efficacy and safety of postdischarge administration of enoxaparin in the prevention of deep venous thrombosis after total hip replacement. A prospective randomised double-blind placebo-controlled trial. Drugs, 1996, Volume: 52 Suppl 7 Topics: Aged; Anticoagulants; Double-Blind Method; Enoxaparin; Female; Hemorrhage; Hip Prosthesis; Humans; M	1996
Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: a double-blind randomized multicentre trial with venographic assessment. ENOXACAN Study Group. The British journal of surgery, 1997, Volume: 84, Issue:8 Topics: Abdominal Neoplasms; Adult; Aged; Aged, 80 and over; Anticoagulants; Blood Loss, Surgical; Double-Bl	1997
Sequential mechanical and pharmacological thromboprophylaxis in the surgery of hip fractures. A pilot study. International orthopaedics, 1997, Volume: 21, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Combined Modality Therapy; Enoxaparin; Female; Femor	1997
A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement. The New England journal of medicine, 1997, Nov-06, Volume: 337, Issue:19 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Double-B	1997
A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prévention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group. The New England journal of medicine, 1998, Feb-12, Volume: 338, Issue:7 Topics: Aged; Anticoagulants; Combined Modality Therapy; Enoxaparin; Female; Hemorrhage; Heparin; Humans; Ma	1998
A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prévention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group. The New England journal of medicine, 1998, Feb-12, Volume: 338, Issue:7 Topics: Aged; Anticoagulants; Combined Modality Therapy; Enoxaparin; Female; Hemorrhage; Heparin; Humans; Ma	1998
A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prévention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group. The New England journal of medicine, 1998, Feb-12, Volume: 338, Issue:7 Topics: Aged; Anticoagulants; Combined Modality Therapy; Enoxaparin; Female; Hemorrhage; Heparin; Humans; Ma	1998
A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prévention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group. The New England journal of medicine, 1998, Feb-12, Volume: 338, Issue:7 Topics: Aged; Anticoagulants; Combined Modality Therapy; Enoxaparin; Female; Hemorrhage; Heparin; Humans; Ma	1998
Enoxaparin plus compression stockings compared with compression stockings alone in the prevention of venous thromboembolism after elective neurosurgery. The New England journal of medicine, 1998, Jul-09, Volume: 339, Issue:2 Topics: Adult; Aged; Anticoagulants; Bandages; Combined Modality Therapy; Double-Blind Method; Elective Surg	1998
The incidence of symptomatic venous thromboembolism after enoxaparin prophylaxis in lower extremity arthroplasty: a cohort study of 1,984 patients. Canadian Collaborative Group. Chest, 1998, Volume: 114, Issue:2 Suppl Ev Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Cohort Studie	1998
Out-of-hospital prophylaxis with low-molecular-weight heparin in hip surgery: the French study--venographic outcome at 35 days. Chest, 1998, Volume: 114, Issue:2 Suppl Ev Topics: Aged; Anti-Bacterial Agents; Arthroplasty, Replacement, Hip; Enoxaparin; Female; Follow-Up Studies;	1998
Out-of-hospital prophylaxis with low-molecular-weight heparin in hip surgery: the Swedish study. Chest, 1998, Volume: 114, Issue:2 Suppl Ev Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Enoxaparin; Humans; Postoperative Complications; Rad	1998
Enoxaparin increases the incidence of postoperative intracranial hemorrhage when initiated preoperatively for deep venous thrombosis prophylaxis in patients with brain tumors. Neurosurgery, 1998, Volume: 43, Issue:5 Topics: Adult; Aged; Anticoagulants; Brain Neoplasms; Cerebral Hemorrhage; Enoxaparin; Female; Humans; Male;	1998
Prevention of deep vein thrombosis after hip replacement--comparison between two low-molecular heparins, tinzaparin and enoxaparin. Thrombosis and haemostasis, 1999, Volume: 81, Issue:1 Topics: Adult; Aged; Arthroplasty, Replacement, Hip; Double-Blind Method; Enoxaparin; Female; Fibrinolytic A	1999
Comparison of enoxaparin and warfarin for the prevention of venous thromboembolic disease after total hip arthroplasty. Evaluation during hospitalization and three months after discharge. The Journal of bone and joint surgery. American volume, 1999, Volume: 81, Issue:7 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Dose-Response Relationship, Drug; Drug A	1999
Venographic comparison of subcutaneous low-molecular weight heparin with oral anticoagulant therapy in the long-term treatment of deep venous thrombosis. Journal of vascular surgery, 1999, Volume: 30, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Coumarins; Enoxaparin; Female; Follow-Up Studies; He	1999
Prevention of deep vein thrombosis after hip replacement. Thrombosis and haemostasis, 2000, Volume: 83, Issue:1 Topics: Arthroplasty, Replacement, Hip; Double-Blind Method; Enoxaparin; Fibrinolytic Agents; Heparin, Low-M	2000
[Médenox study]. Presse medicale (Paris, France : 1983), 2000, Feb-19, Volume: 29, Issue:6 Topics: Anticoagulants; Dose-Response Relationship, Drug; Enoxaparin; Hospitalization; Humans; Prospective S	2000
Low molecular weight heparin (enoxaparin) versus oral anticoagulant therapy (acenocoumarol) in the long-term treatment of deep venous thrombosis in the elderly: a randomized trial. Thrombosis and haemostasis, 2000, Volume: 84, Issue:4 Topics: Acenocoumarol; Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Enoxaparin; Female; He	2000
[The frequency of peri- and postoperative bleeding after prophylactic treatment with enoxapirin in patients with post-traumatic deep vein thrombosis]. Chirurgia narzadow ruchu i ortopedia polska, 2000, Volume: 65, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Blood Transfusion; Enoxaparin; Female; Humans; Leg I	2000
[Prospective randomized study comparing the effectiveness and tolerance of various low-molecular-weight heparins in high risk patients]. Zentralblatt fur Chirurgie, 2001, Volume: 126, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replac	2001
Cost-effectiveness of prolonged out-of-hospital prophylaxis with low-molecular-weight heparin following total hip replacement. Haemostasis, 2000, Volume: 30 Suppl 2 Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Cost-Benefit Analysis; Drug Costs; Enoxaparin; Home	2000
Prevention of deep vein thrombosis after total hip replacement. The effect of low-molecular-weight heparin with spinal and general anaesthesia. The Journal of bone and joint surgery. British volume, 1991, Volume: 73, Issue:3 Topics: Aged; Anesthesia, General; Anesthesia, Spinal; Blood Loss, Surgical; Enoxaparin; Female; Hip Prosthe	1991
Risk factors and coagulation parameters in relationship to phlebographic response and clinical outcome in the treatment of acute deep vein thrombosis. Thrombosis and haemostasis, 2003, Volume: 89, Issue:2 Topics: Acute Disease; Adult; Aged; Anticoagulants; Antithrombin III; Biomarkers; Drug Administration Schedu	2003
An international multicentre study: Clivarin in the prevention of venous thromboembolism in patients undergoing general surgery. Report of the International Clivarin Assessment Group. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 1993, Volume: 4 Suppl 1 Topics: Adult; Aged; Double-Blind Method; Female; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Inciden	1993
Efficacy and safety of a low-molecular-weight heparin and standard unfractionated heparin for prophylaxis of postoperative venous thromboembolism: European multicenter trial. World journal of surgery, 1997, Volume: 21, Issue:1 Topics: Adult; Aged; Anticoagulants; Double-Blind Method; Female; Hemorrhage; Heparin; Heparin, Low-Molecula	1997
Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. The New England journal of medicine, 1997, 09-04, Volume: 337, Issue:10 Topics: Anticoagulants; Death, Sudden; Female; Hemorrhage; Heparin; Heparin, Low-Molecular-Weight; Humans; M	1997
[Fully automated injection pen for prevention of thrombosis. Tolerance, convenience and patient compliance]. MMW Fortschritte der Medizin, 1999, Jul-01, Volume: 141, Issue:26 Topics: Heparin, Low-Molecular-Weight; Humans; Injections, Jet; Patient Compliance; Postoperative Complicati	1999
A randomized trial of dalteparin compared with ibuprofen for the treatment of superficial thrombophlebitis. Journal of thrombosis and haemostasis : JTH, 2012, Volume: 10, Issue:5 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Dalte	2012
The epidemiology of peripheral vein complications: evaluation of the efficiency of differing methods for the maintenance of catheter patency and thrombophlebitis prevention. Journal of evaluation in clinical practice, 2005, Volume: 11, Issue:1 Topics: Catheterization, Peripheral; Dalteparin; Elective Surgical Procedures; Female; Fibrinolytic Agents;	2005
Comparison of once-daily subcutaneous Fragmin with continuous intravenous unfractionated heparin in the treatment of deep vein thrombosis. Thrombosis and haemostasis, 1994, Volume: 72, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Dalteparin; Drug Administration Schedule; Factor Xa Inhibitors; Fema	1994
Adjusted versus fixed doses of the low-molecular-weight heparin fragmin in the treatment of deep vein thrombosis. Fragmin-Study Group. Thrombosis and haemostasis, 1994, Volume: 71, Issue:6 Topics: Acute Disease; Adult; Aged; Dalteparin; Dose-Response Relationship, Drug; Female; Humans; Male; Midd	1994
Upper extremity deep venous thrombosis in cancer patients with venous access devices--prophylaxis with a low molecular weight heparin (Fragmin). Thrombosis and haemostasis, 1996, Volume: 75, Issue:2 Topics: Adult; Aged; Anticoagulants; Arm; Catheterization, Central Venous; Dalteparin; Female; Humans; Incid	1996
Once-daily subcutaneous dalteparin, a low molecular weight heparin, for the initial treatment of acute deep vein thrombosis. Thrombosis and haemostasis, 1996, Volume: 76, Issue:2 Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Dalteparin; Drug Administ	1996
Risk factors for major thromboembolism and bleeding tendency after elective general surgical operations. The Fragmin Multicentre Study Group. The European journal of surgery = Acta chirurgica, 1996, Volume: 162, Issue:10 Topics: Abdomen; Anticoagulants; Dalteparin; Elective Surgical Procedures; Hemorrhagic Disorders; Humans; Mu	1996
The antithrombotic potential of dalteparin in man assessed indirectly by Wessler's technique. Thrombosis and haemostasis, 1996, Volume: 76, Issue:6 Topics: Animals; Anticoagulants; Blood Coagulation; Dalteparin; Humans; Rats; Thrombophlebitis	1996
Antithrombotic prophylaxis in patients undergoing laparoscopic cholecystectomy. Thrombosis research, 1997, May-01, Volume: 86, Issue:3 Topics: Adult; Aged; Anticoagulants; Cholecystectomy, Laparoscopic; Dalteparin; Double-Blind Method; Female;	1997
A 6-month venographic follow-up in 164 patients with acute deep vein thrombosis. Thrombosis and haemostasis, 1997, Volume: 78, Issue:2 Topics: Acute Disease; Aged; Anticoagulants; Dalteparin; Female; Follow-Up Studies; Heparin; Heparin, Low-Mo	1997
Prevention of deep-vein thrombosis after total hip arthroplasty. Comparison of warfarin and dalteparin. The Journal of bone and joint surgery. American volume, 1997, Volume: 79, Issue:9 Topics: Anticoagulants; Blood Loss, Surgical; Dalteparin; Female; Hemorrhage; Hip Prosthesis; Humans; Male;	1997
Compression and walking versus bed rest in the treatment of proximal deep venous thrombosis with low molecular weight heparin. Journal of vascular surgery, 2000, Volume: 32, Issue:5 Topics: Acute Disease; Adult; Aged; Analysis of Variance; Anticoagulants; Bandages; Bed Rest; Combined Modal	2000
Thromboprophylaxis by low-molecular-weight heparin in elective hip surgery. A placebo controlled study. The Journal of bone and joint surgery. British volume, 1991, Volume: 73, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Blood Loss, Surgical; Dalteparin; Double-Blind Method; Female; Fibri	1991
Is there a need for long-term thromboprophylaxis following general surgery? Haemostasis, 1993, Volume: 23 Suppl 1 Topics: Bandages; Clinical Trials as Topic; Combined Modality Therapy; Double-Blind Method; Follow-Up Studie	1993
Colour Doppler flow imaging ultrasonography versus venography as screening method for asymptomatic postoperative deep venous thrombosis. European journal of radiology, 1995, Volume: 20, Issue:3 Topics: Abdomen; Bandages; Elective Surgical Procedures; Femoral Vein; Fibrinolytic Agents; Heparin, Low-Mol	1995
Thromboprophylaxis with a low molecular weight heparin (tinzaparin) in emergency abdominal surgery. A double-blind multicenter trial. VASA. Zeitschrift fur Gefasskrankheiten, 1996, Volume: 25, Issue:2 Topics: Abdomen; Adult; Aged; Aged, 80 and over; Double-Blind Method; Emergencies; Female; Fibrinolytic Agen	1996
Incidence and prevention of deep venous thrombosis occurring late after general surgery: randomised controlled study of prolonged thromboprophylaxis. The European journal of surgery = Acta chirurgica, 1998, Volume: 164, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Female; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans;	1998
[Lengthened activated thromboplastin time in the course of tinzaparin therapy of accidental venous thromboembolism. Pilot study]. Presse medicale (Paris, France : 1983), 1998, Apr-11, Volume: 27, Issue:14 Topics: Adult; Aged; Aged, 80 and over; Female; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans;	1998
Monitoring the anticoagulant effects of a low molecular weight heparin preparation. Correlation of assays in orthopedic surgery patients receiving ardeparin sodium for prophylaxis of deep venous thrombosis. American journal of clinical pathology, 1995, Volume: 103, Issue:5 Topics: Anticoagulants; Female; Heparin, Low-Molecular-Weight; Hip Prosthesis; Humans; Knee Prosthesis; Male	1995
Efficacy and safety of low molecular weight heparin (ardeparin sodium) compared to warfarin for the prevention of venous thromboembolism after total knee replacement surgery: a double-blind, dose-ranging study. Ardeparin Arthroplasty Study Group. Thrombosis and haemostasis, 1997, Volume: 77, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Female; Heparin, Low-Molecular-	1997

Article	Year
Pharmacological properties of CY 216 and of its ACLM and BCLM components in the rabbit. Thrombosis and haemostasis, 1994, Volume: 72, Issue:2 Topics: Animals; Factor Xa Inhibitors; Hemorrhage; Infusions, Intravenous; Injections, Intravenous; Injectio	1994
[Comparative study of the efficacy of a low dose of antivitamin K and a preventive dose of low molecular weight heparin in the prevention of relapses of deep venous thrombosis after curative treatment in the aged subject]. Journal des maladies vasculaires, 1994, Volume: 19, Issue:1 Topics: 4-Hydroxycoumarins; Aged; Anticoagulants; Dose-Response Relationship, Drug; Hemorrhage; Humans; Inde	1994
[The use of fraxiparin in orthopedic trauma patients to prevent and treat pulmonary embolism and deep venous thrombosis of the extremities]. Terapevticheskii arkhiv, 1993, Volume: 65, Issue:10 Topics: Adult; Drug Evaluation; Female; Fractures, Bone; Humans; Knee Injuries; Male; Middle Aged; Nadropari	1993
[Prevention of thrombosis with fraxiparin 0.3 after ambulatory surgery]. Fortschritte der Medizin, 1996, Apr-30, Volume: 114, Issue:12 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ambulatory Surgical Procedures; Anticoagulants; Dose-Res	1996
Studies raise possibility of home therapy for acute deep-vein thrombosis. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 1996, May-01, Volume: 53, Issue:9 Topics: Enoxaparin; Fibrinolytic Agents; Home Infusion Therapy; Humans; Infusions, Intravenous; Nadroparin;	1996
[Thromboembolism prophylaxis in pregnancy and labor]. Ginekologia polska, 1996, Volume: 67, Issue:11 Topics: Anticoagulants; Drug Administration Schedule; Female; Heart Valve Prosthesis; Hemostasis; Humans; Na	1996
Subcutaneous low-molecular-weight heparin for treatment of Trousseau's syndrome. Annals of hematology, 1997, Volume: 75, Issue:4 Topics: Aged; Anticoagulants; Carcinoma, Bronchogenic; Carcinoma, Non-Small-Cell Lung; Humans; Injections, S	1997
Efficacy of prevention of thromboembolic complications with LMW-heparin in experiment. Acta chirurgica Hungarica, 1997, Volume: 36, Issue:1-4 Topics: Animals; Anticoagulants; Arthroplasty, Replacement, Hip; Disease Models, Animal; Dogs; Factor Xa Inh	1997
SimpliRED D-dimer assay: comparability of capillary and citrated venous whole blood, between-assay variability, and performance of the test for exclusion of deep vein thrombosis in symptomatic outpatients. Thrombosis and haemostasis, 1998, Volume: 79, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Biomarkers; Blood Specimen Collection; Capillaries;	1998
Economic evaluation of the use of nadroparin calcium in the prophylaxis of deep vein thrombosis and pulmonary embolism in surgical patients in Italy. PharmacoEconomics, 1997, Volume: 12, Issue:4 Topics: Fibrinolytic Agents; Humans; Italy; Nadroparin; Postoperative Complications; Pulmonary Embolism; Thr	1997
Prevention of deep-vein thrombosis after total knee replacement. The Journal of bone and joint surgery. British volume, 2000, Volume: 82, Issue:2 Topics: Arthroplasty, Replacement, Knee; Humans; Nadroparin; Physical Therapy Modalities; Postoperative Comp	2000
[Successful treatment of subclavian thrombophlebitis in a patient with pulmonary tuberculosis]. Problemy tuberkuleza, 2001, Issue:5 Topics: Anticoagulants; Blood; Catheterization, Central Venous; Fibrinolytic Agents; Humans; Male; Middle Ag	2001
[Cerebral thrombophlebitis: complication of frontotemporoparietal cellulitis in a child victim of human bite]. The Pan African medical journal, 2020, Volume: 35 Topics: Adrenal Cortex Hormones; Analgesics; Bites, Human; Cellulitis; Child; Consciousness Disorders; Enoxa	2020
COVID-19 patient with immune thrombocytopenic purpura. International journal of laboratory hematology, 2020, Volume: 42, Issue:6 Topics: Aged, 80 and over; Anticoagulants; Autoantibodies; Betacoronavirus; Combined Modality Therapy; Coron	2020
Successful treatment of penile Mondor's disease with infliximab in a patient with Behçet's disease. Rheumatology (Oxford, England), 2021, 11-03, Volume: 60, Issue:11 Topics: Adult; Antirheumatic Agents; Behcet Syndrome; Enoxaparin; Humans; Infliximab; Male; Penile Diseases;	2021
Synchronous Cardiopulmonary Consequences of the Hypercoagulable State Associated With Cancer. Archivos de bronconeumologia, 2019, Volume: 55, Issue:6 Topics: Adenocarcinoma; Anticoagulants; Brain Ischemia; Computed Tomography Angiography; Endocarditis, Non-I	2019
Penile Mondor's syndrome after endovenous treatment of the great saphenous vein with 1470 nm diode laser. Phlebology, 2015, Volume: 30, Issue:3 Topics: Diclofenac; Endovascular Procedures; Enoxaparin; Humans; Laser Therapy; Male; Middle Aged; Postopera	2015
Deep thrombophlebitis masked by peripheral arthritis in Henoch-Schönlein purpura. International journal of rheumatic diseases, 2016, Volume: 19, Issue:12 Topics: Adolescent; Anticoagulants; Arthritis; Enoxaparin; Humans; IgA Vasculitis; Male; Popliteal Vein; Thr	2016
Activated clotting time monitoring during osteocutaneous free fibula flap surgery. Plastic and reconstructive surgery, 2015, Volume: 135, Issue:2 Topics: Aged; Anticoagulants; Blood Coagulation; Carcinoma, Squamous Cell; Enoxaparin; Facial Neoplasms; Fem	2015
Facial vein thrombophlebitis: an uncommon complication of sinusitis. Pediatric radiology, 2015, Volume: 45, Issue:8 Topics: Anti-Bacterial Agents; Anticoagulants; Cefdinir; Cephalosporins; Child; Contrast Media; Diagnosis, D	2015
Pulmonary embolism associated with protein C deficiency and abuse of anabolic-androgen steroids. Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 2010, Volume: 16, Issue:2 Topics: Anticoagulants; Blood Coagulation Factors; Dalteparin; Doping in Sports; Enoxaparin; Hematoma, Subdu	2010
[Parturient at full term with inferior vena cava thrombosis: anesthesia during surgical delivery]. Revista espanola de anestesiologia y reanimacion, 2010, Volume: 57, Issue:5 Topics: Adult; Anesthesia, General; Anesthesia, Obstetrical; Anticoagulants; Cesarean Section; Emergencies;	2010
Progressive thrombosis in a 13-year-old girl with trisomy 21 under therapy with low molecular weight heparin. Klinische Padiatrie, 2011, Volume: 223, Issue:3 Topics: Adolescent; Antibodies, Antiphospholipid; Anticoagulants; Antiphospholipid Syndrome; Antithrombins;	2011
Septic thrombophlebitis of portal vein: unusual presentation of appendicitis. The American surgeon, 2011, Volume: 77, Issue:9 Topics: Adult; Anticoagulants; Appendectomy; Appendicitis; Diagnosis, Differential; Enoxaparin; Follow-Up St	2011
Effectiveness of low-dose prolonged infusion of tissue plasminogen activator in a nonagenarian patient with acute pulmonary embolism and main pulmonary artery thrombus. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2013, Volume: 24, Issue:1 Topics: Acute Disease; Aged, 80 and over; Anticoagulants; Arterial Occlusive Diseases; Drug Substitution; Em	2013
[New synthetic antithrombotic agent. In secondary prevention conclusive, too]. MMW Fortschritte der Medizin, 2003, Mar-27, Volume: 145, Issue:13 Topics: Anticoagulants; Clinical Trials as Topic; Enoxaparin; Fibrinolytic Agents; Fondaparinux; Heparin; Hu	2003
Superficial venous thrombosis associated with congenital absence of the inferior vena cava and previous episode of deep venous thrombosis. American journal of hematology, 2008, Volume: 83, Issue:3 Topics: Adult; Anticoagulants; Enoxaparin; Humans; Male; Thrombophlebitis; Tomography, X-Ray Computed; Treat	2008
Unprovoked recurrent venous thrombosis: prediction by D-dimer and clinical risk factors. Journal of thrombosis and haemostasis : JTH, 2008, Volume: 6, Issue:4 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Confounding Factors, Epidemiologic; Cont	2008
Comment: enoxaparin--the low-molecular-weight heparin for prevention of postoperative thromboembolic complications. The Annals of pharmacotherapy, 1994, Volume: 28, Issue:6 Topics: Enoxaparin; Humans; Postoperative Complications; Thromboembolism; Thrombophlebitis; Warfarin	1994
Economic evaluation of standard heparin and enoxaparin for prophylaxis against deep vein thrombosis in elective hip surgery. The British journal of surgery, 1994, Volume: 81, Issue:12 Topics: Decision Trees; Drug Costs; Elective Surgical Procedures; Enoxaparin; Heparin; Hip Joint; Humans; Se	1994
Low-molecular-weight heparin and epidural/spinal anaesthesia--is there a risk? Acta anaesthesiologica Scandinavica, 1994, Volume: 38, Issue:3 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anesthesia, Epidural; Anesthesia, Spinal; Enoxaparin; Fe	1994
[General perioperative prevention of thromboembolism in gynecology with low-molecular weight heparin: clinical experiences with enoxaparin over 7 years]. Zentralblatt fur Gynakologie, 1995, Volume: 117, Issue:11 Topics: Adult; Aged; Anticoagulants; Blood Coagulation Tests; Combined Modality Therapy; Dose-Response Relat	1995
Post-discharge deep-vein thrombosis after orthopaedic surgery. Lancet (London, England), 1996, Oct-26, Volume: 348, Issue:9035 Topics: Anticoagulants; Enoxaparin; Hip Prosthesis; Humans; Phlebography; Postoperative Complications; Throm	1996
Prevention of venous thrombosis in knee arthroplasty. Annals of internal medicine, 1997, Jan-15, Volume: 126, Issue:2 Topics: Anticoagulants; Enoxaparin; Humans; Knee Prosthesis; Postoperative Complications; Thrombophlebitis;	1997
Prevention of venous thrombosis in knee arthroplasty. Annals of internal medicine, 1997, Jan-15, Volume: 126, Issue:2 Topics: Anticoagulants; Enoxaparin; Humans; Knee Prosthesis; Postoperative Complications; Research Design; T	1997
Enoxaparin as prophylaxis against thromboembolism after total hip replacement. The New England journal of medicine, 1997, Feb-20, Volume: 336, Issue:8 Topics: Anticoagulants; Enoxaparin; Hip Prosthesis; Humans; Radiography; Thromboembolism; Thrombophlebitis	1997
Enoxaparin-associated dermal necrosis: a consequence of cross-reactivity with heparin-mediated antibodies. The Annals of pharmacotherapy, 1997, Volume: 31, Issue:3 Topics: Adult; Antibodies; Anticoagulants; Cross Reactions; Drug Eruptions; Enoxaparin; Female; Heparin; Hum	1997
A short course of low-molecular-weight heparin to prevent deep venous thrombosis after elective total hip replacement. Canadian journal of surgery. Journal canadien de chirurgie, 1997, Volume: 40, Issue:2 Topics: Anticoagulants; Chi-Square Distribution; Drug Evaluation; Elective Surgical Procedures; Enoxaparin;	1997
Pharmacoeconomic model of enoxaparin versus heparin for prevention of deep vein thrombosis after total hip replacement. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 1997, May-15, Volume: 54, Issue:10 Topics: Anticoagulants; Cost-Benefit Analysis; Enoxaparin; Heparin; Hip Prosthesis; Humans; Models, Economic	1997
An unexpected complication of DVT prophylaxis. Acta orthopaedica Belgica, 1997, Volume: 63, Issue:2 Topics: Aged; Anticoagulants; Chemoprevention; Enoxaparin; Female; Hemorrhage; Hip Joint; Hip Prosthesis; Hu	1997
Pharmacy-managed program for home treatment of deep vein thrombosis with enoxaparin. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 1997, Sep-01, Volume: 54, Issue:17 Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Enoxaparin; Female; Healt	1997
Antithrombotic agents and thromboembolic disease. The New England journal of medicine, 1997, Nov-06, Volume: 337, Issue:19 Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Enoxaparin; Fibrinolytic Agents; Hirudin Therapy; Hi	1997
Internal jugular vein thrombosis in patients with ovarian hyperstimulation syndrome. Fertility and sterility, 1998, Volume: 69, Issue:1 Topics: Adult; Anticoagulants; Enoxaparin; Factor V; Female; Humans; Jugular Veins; Ovarian Hyperstimulation	1998
Monitoring of patients with deep-vein thrombosis during and after anticoagulation with D-dimer. Lancet (London, England), 1998, Feb-21, Volume: 351, Issue:9102 Topics: Adult; Aged; Anticoagulants; Enoxaparin; Female; Fibrin Fibrinogen Degradation Products; Humans; Mal	1998
Recombinant hirudin compared with low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement. The New England journal of medicine, 1998, Mar-26, Volume: 338, Issue:13 Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Enoxaparin; Hirudin Therapy; Hirudins; Humans; Posto	1998
Warfarin vs enoxaparin for deep venous thrombosis prophylaxis after total hip & total knee arthroplasty: a cost comparison. The Journal of the Kentucky Medical Association, 1998, Volume: 96, Issue:4 Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Cost-Benefit Analys	1998
Deep venous thrombosis in a preterm newborn of a mother with activated protein C resistance. Clinical pediatrics, 1998, Volume: 37, Issue:6 Topics: Adult; Blood Coagulation Disorders; Enoxaparin; Female; Humans; Infant, Newborn; Infant, Premature,	1998
Cost effectiveness of low-molecular weight heparin versus warfarin following hip replacement surgery. Journal of the National Medical Association, 1998, Volume: 90, Issue:11 Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Black or African American; Cost-Benefit Analysis; Di	1998
Treatment of acute deep vein thrombosis in spinal cord injured patients with enoxaparin: a cost analysis. The journal of spinal cord medicine, 1998, Volume: 21, Issue:3 Topics: Adult; Anticoagulants; Cost-Benefit Analysis; Costs and Cost Analysis; Enoxaparin; Female; Heparin;	1998
Prevention of deep vein thrombosis after hip replacement--reply. Thrombosis and haemostasis, 2000, Volume: 84, Issue:4 Topics: Arthroplasty, Replacement, Hip; Enoxaparin; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Huma	2000
Utilization and outcomes of enoxaparin treatment for deep-vein thrombosis in a tertiary-care hospital. American journal of hematology, 2000, Volume: 65, Issue:4 Topics: Enoxaparin; Fibrinolytic Agents; Humans; Outpatients; Retrospective Studies; Thrombophlebitis; Treat	2000
Deep vein thrombosis during enoxaparin prophylactic treatment in a young pregnant woman homozygous for factor V Leiden and heterozygous for the G127-->a mutation in the thrombomodulin gene. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2000, Volume: 11, Issue:8 Topics: Adult; Anticoagulants; Enoxaparin; Factor V; Female; Humans; Point Mutation; Pregnancy; Pregnancy Co	2000
Cerebral vein thrombosis and lupus anticoagulant antibodies. Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 2001, Volume: 7, Issue:3 Topics: Adult; Anticoagulants; Antiphospholipid Syndrome; Autoimmune Diseases; Enoxaparin; Female; Humans; L	2001
[Low-molecular-weight heparin in deep venous thrombosis. Dosage for all weight classes]. MMW Fortschritte der Medizin, 2003, Jun-12, Volume: 145, Issue:24 Topics: Anticoagulants; Body Weight; Clinical Trials as Topic; Fibrinolytic Agents; Hemorrhage; Heparin; Hep	2003
[Body weight adapted anticoagulation is passé. Thrombosis therapy without scales]. MMW Fortschritte der Medizin, 2003, Dec-11, Volume: 145, Issue:50 Topics: Body Weight; Clinical Trials as Topic; Follow-Up Studies; Heparin, Low-Molecular-Weight; Humans; Inj	2003
Should low molecular weight heparin dosing be based on anti-Xa assays in antiphospholipid syndrome? Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2013, Volume: 24, Issue:1 Topics: Adult; Anti-Bacterial Agents; Antibodies, Anticardiolipin; Anticoagulants; Antiphospholipid Syndrome	2013
Acute generalized exanthematous pustulosis from dalteparin. Journal of the American Academy of Dermatology, 2007, Volume: 57, Issue:4 Topics: Acute Disease; Anticoagulants; Dalteparin; Drug Eruptions; Exanthema; Female; Humans; Injections; Mi	2007
Dalteparin--another low-molecular-weight heparin. The Medical letter on drugs and therapeutics, 1995, Dec-08, Volume: 37, Issue:963 Topics: Anticoagulants; Controlled Clinical Trials as Topic; Dalteparin; Drug Costs; Heparin; Humans; Molecu	1995
Increased activation of coagulation and formation of late deep venous thrombosis following discontinuation of thromboprophylaxis after hip replacement surgery. Thrombosis research, 1995, Nov-15, Volume: 80, Issue:4 Topics: Aged; Anticoagulants; Antithrombin III; Dalteparin; Female; Hip Prosthesis; Humans; Male; Peptide Hy	1995
Is colour Doppler ultrasound a sensitive screening method in diagnosing deep vein thrombosis after hip surgery? Thrombosis and haemostasis, 1996, Volume: 75, Issue:2 Topics: Anticoagulants; Dalteparin; Dextrans; Hip Fractures; Hip Prosthesis; Hirudin Therapy; Hirudins; Huma	1996
Heparin stimulation of the inhibition of activated protein C and other enzymes by human protein C inhibitor--influence of the molecular weightof heparin and ionic strength. Thrombosis and haemostasis, 1996, Volume: 76, Issue:6 Topics: Animals; Dalteparin; Humans; Male; Rats; Thrombophlebitis	1996
Thromboprophylaxis with low molecular weight heparin (Fragmin) in high risk pregnancies. Thrombosis and haemostasis, 1997, Volume: 77, Issue:1 Topics: Adult; Anticoagulants; Dalteparin; Female; Humans; Injections, Subcutaneous; Pregnancy; Pregnancy Co	1997
[Does the pork/cat syndrome constitute a predisposition to heparin allergy?]. Allergie et immunologie, 1997, Volume: 29, Issue:2 Topics: Adult; Allergens; Animals; Asthma; Blotting, Western; Cats; Cross Reactions; Dalteparin; Drug Erupti	1997
Antithrombotic effect of two low molecular weight thrombin inhibitors and a low-molecular weight heparin in a caval vein thrombosis model in the rat. Thrombosis and haemostasis, 1997, Volume: 78, Issue:5 Topics: Animals; Azetidines; Benzylamines; Dalteparin; Disease Models, Animal; Fibrinolytic Agents; Glycine;	1997
Antithrombotic effects of YM-60828, a newly synthesized factor Xa inhibitor, in rat thrombosis models and its effects on bleeding time. British journal of pharmacology, 1998, Volume: 123, Issue:1 Topics: Animals; Anticoagulants; Arginine; Arteriovenous Shunt, Surgical; Bleeding Time; Blood Proteins; Dal	1998
Long-term clinical follow-up in 265 patients with deep venous thrombosis initially treated with either unfractionated heparin or dalteparin: a retrospective analysis. Thrombosis and haemostasis, 1999, Volume: 82, Issue:4 Topics: Anticoagulants; Dalteparin; Follow-Up Studies; Heparin; Humans; Infusions, Intravenous; Retrospectiv	1999
Practicability and quality of outpatient management of acute deep venous thrombosis. Journal of vascular surgery, 2000, Volume: 32, Issue:5 Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Ambulatory Care; Anticoagulants; Bandages	2000
Acute dyspnea in a woman with swelling of the left leg treated with low molecular weight heparine. The American journal of emergency medicine, 2001, Volume: 19, Issue:3 Topics: Abdominal Muscles; Acute Disease; Aged; Anticoagulants; Blood Transfusion; Dalteparin; Dyspnea; Emer	2001
[Out-patient treatment of deep vein thrombosis: management and experience of two vascular care centres in Germany]. Deutsche medizinische Wochenschrift (1946), 2001, Oct-19, Volume: 126, Issue:42 Topics: Acute Disease; Aged; Anticoagulants; Dalteparin; Female; Fibrinolytic Agents; Follow-Up Studies; Hum	2001
Retroperitoneal haematoma and tinzaparin. Current medical research and opinion, 2003, Volume: 19, Issue:3 Topics: Aged; Female; Fibrinolytic Agents; Hematoma; Heparin, Low-Molecular-Weight; Humans; Retroperitoneal	2003
Tinzaparin as an antithrombotic: an overview. Hospital medicine (London, England : 1998), 1998, Volume: 59, Issue:2 Topics: Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Injections, Subcutaneous; Pulmonary Embo	1998
Ardeparin cleared for marketing. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 1997, Jul-15, Volume: 54, Issue:14 Topics: Drug Approval; Heparin, Low-Molecular-Weight; Humans; Knee Prosthesis; Thrombophlebitis; United Stat	1997
Ardeparin and danaparoid for prevention of deep vein thrombosis. The Medical letter on drugs and therapeutics, 1997, Oct-10, Volume: 39, Issue:1011 Topics: Abdomen; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Chondroiti	1997

dalteparin and Phlegmasia Alba Dolens